Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) CEO Sells 84,640 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 84,640 shares of Tempus AI stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $80.87, for a total transaction of $6,844,836.80. Following the completion of the sale, the chief executive officer now owns 4,964,820 shares of the company’s stock, valued at $401,504,993.40. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Tempus AI Price Performance

NASDAQ TEM traded down $8.99 during mid-day trading on Thursday, reaching $76.72. 20,409,815 shares of the stock were exchanged, compared to its average volume of 14,385,644. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The business’s fifty day simple moving average is $49.05 and its 200 day simple moving average is $51.26. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Wall Street Analysts Forecast Growth

Several research firms have commented on TEM. TD Cowen restated a “buy” rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Bank of America lifted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a research report on Tuesday, January 14th. Guggenheim initiated coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target for the company. Finally, William Blair cut shares of Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Institutional Trading of Tempus AI

A number of hedge funds have recently bought and sold shares of TEM. ARK Investment Management LLC boosted its position in Tempus AI by 132.1% during the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock worth $186,343,000 after acquiring an additional 3,141,487 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its position in Tempus AI by 166.0% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after acquiring an additional 2,021,394 shares during the last quarter. Franklin Resources Inc. boosted its position in Tempus AI by 240.5% during the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company’s stock worth $93,251,000 after acquiring an additional 1,950,862 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Tempus AI by 86,947.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company’s stock worth $55,836,000 after acquiring an additional 1,651,996 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.